# Site-specific Indolation of Proline-based Peptides via

# Copper(II)-Catalyzed oxidative coupling of tertiary amine N-oxides

Xiaowei Wu, ‡ Dengyou Zhang, ‡ Shengbin Zhou, Feng Gao, Hong Liu\*

CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, P. R. China.

E-mail: hliu@mail.shcnc.ac.cn

# **Table of Contents**


(A) General Methods	2
<ul> <li>(B) General Procedures</li></ul>	3
	7
	35
(F) Copies of <sup>1</sup> H NMR and <sup>13</sup> C NMR Spectra for the Products	47
(G) Reference	

# (A) General Methods

The reagents (chemicals) were purchased from commercial sources, and used without further purification. Analytical thin layer chromatography (TLC) was HSGF 254 (0.15-0.2 mm thickness). Preparative thin layer chromatography (PTLC) was HSGF 254 (0.4-0.5 mm thickness). All products were characterized by their NMR and MS spectra. <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a 400 MHz, 500 MHz or 600 MHz instrument. Chemical shifts were reported in parts per million (ppm,  $\delta$ ) downfield from tetramethylsilane. Proton coupling patterns are described as singlet (s), doublet (d), triplet (t), quartet (q), multiplet (m), doublet of doublets (dd) and broad (br). High-resolution mass spectra (HRMS) were measured on Micromass Ultra Q-TOF spectrometer. The determination of dr was performed via LC/MS analysis using Agilent 6120 spectrometer. Optical rotations were measured using a 1 mL cell with a 10 mm path length on an Auto pol V PLVS matic polarimeter and are reported as follows: [ $\alpha$ ] <sup>25</sup><sub>D</sub> (c: g/100 mL, in solvent).


# **(B)** General Procedures

General Procedure for the Preparation of Dipeptide Derivative 5a-5h.



The synthesis of benzyl-L-prolyl-L-leucine methyl ester **5a** is representative. To a solution of benzyl-L-proline **6** (1 g, 4.87 mmol) and L-leucine methyl ester hydrochloride **8a** (0.97 g, 5.36 mmol) in DIPEA (1.6 mL, 9.74 mmol) and dichloromethane (20 mL) was added HATU (2 g, 5.36 mmol) at 0 °C. After 30 min, the reaction mixture was allowed to warm up to room temperature and the stirring was continued for 12 h. After the reaction was completed, the mixture was portioned between water and dichloromethane. The combined organic layers were washed with brine, dried, filtered and concentrated. The residue was purified by chromatography on silica gel (PE/EA = 4/1- 2/1) to give **5a** as a colorless oil (1.4 g, yield 86%).

Procedure for the Preparation of Tripeptide Derivative 5i and 5j.



The synthesis of benzyl-L-prolylglycyl-L-valine methyl ester 5i is representative. To a

solution of benzyl-L-proline **6** (2 g, 9.74 mmol) and glycine tert-butyl ester hydrochloride **7** (1.8 g, 10.72 mmol) in DIPEA (3.2 mL, 19.49 mmol) and dichloromethane (40 mL) was added HATU (4.1 g, 10.72 mmol) at room temperature and the stirring was continued for 12 h. The mixture was portioned between water and dichloromethane. The combined organic layers were washed with brine, dried, filtered and concentrated. The residue was purified by chromatography on silica gel (PE/EA = 6/1-4/1) to give **9** as a colorless oil (2.8 g, yield 90%).

To a solution of **9** (2.8 g, 8.79 mmol) in DCM (10 mL) was added trifluoroacetic acid (6.5 mL, 87.9 mmol), and the mixture was stirred for 5 h at rt. The solvent was removed, and the residue was basified with TEA and purified by chromatography on silica gel (DCM/MeOH = 10/1- 5/1) to get compound **10** as a colorless oil (1.5 g, 65%).


To a mixture of benzyl-L-prolylglycine **10** (700 mg, 2.67 mmol) and L-valine methyl ester hydrochloride **8b** (492 mg, 2.94 mmol) in DIPEA (882  $\mu$ L, 5.34 mmol) and dichloromethane (20 mL) was added HATU (1.12 g, 2.94 mmol) at 0 °C. After 30 min, the mixture was allowed to warm up to room temperature and the stirring was continued for overnight. The resulting mixture was diluted with dichloromethane and water, washed with saturated NaHCO<sub>3</sub> aq. and brine. The organic layers were dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated. The residue was purified by chromatography on silica gel (DCM/MeOH = 30/1) to give crude product **5i** as a yellow oil.

## General Procedure for the Preparation of Amine N-Oxides 1.<sup>1</sup>



The synthesis of amine N-Oxide **1a** is representative. To a solution of benzyl-L-prolyl-L-leucine methyl ester **5a** (3 g, 9.02 mmol) in DCM (40 mL) was added 3-Chloroperbenzoic acid (m-CPBA, 2.02 g, 11.73 mmol) at -20 °C. The reaction was stirred for 3h, and then diluted with H<sub>2</sub>O, washed with saturated Na<sub>2</sub>CO<sub>3</sub> aq. and brine. The combined organic phase was dried over with anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated. The residue was purified by chromatography on silica gel (DCM/MeOH = 30/1) to give product **1a** as a white solid (3 g, 95%).


#### General Procedure for the Indolation of Amine N-Oxides 1.



The reaction of amine N-Oxide **1a** with indole **2a** is representative. The dry sealed tube was charged with N-Oxide **1a** (70 mg, 0.2 mmol), indole **2a** (71 mg, 0.6 mmol), CuBr<sub>2</sub> (2 mg, 0.01 mmol), TsOH (7 mg, 0.04 mmol) and 3mL CHCl<sub>3</sub> under Ar atmosphere. The mixture was heated at 50 °C for 36 h. The resulting mixture was diluted with dichloromethane and washed by water. The combined organic layers were dried with Na<sub>2</sub>SO<sub>4</sub>, filtered, concentrated and purified by column


chromatography on silica gel (DCM/MeOH = 50/1-30/1) to give combined products **3a/4a** as a colorless oil (63 mg, yield 70%). The combined products **3a/4a** were purified by preparative thin layer chromatography (PTLC) to give the major product **3a** as a colorless oil.

**Procedure of One-pot Reaction.** 




To a solution of benzyl-L-prolyl-L-phenylalanine methyl ester **5g** (560 mg, 1.53 mmol) in DCM (10 mL) was added m-CPBA (263 mg, 1.53 mmol) at -20 °C. The reaction was stirred for 3h, then the solvent was removed, and indole **2a** (537 mg, 4.58 mmol), CuBr<sub>2</sub> (17 mg, 0.08 mmol), TsOH (53 mg, 0.3 mmol) and 15 mL CHCl<sub>3</sub> were added to the sealed vessel under Ar atmosphere. The reaction was continued for 36 h. The resulting mixture was diluted with dichloromethane and washed with water. The combined organic layers were dried with Na<sub>2</sub>SO<sub>4</sub>, filtered, concentrated and purified by column chromatography on silica gel (DCM/MeOH = 50/1- 30/1) to give combined products **3s/4s** as a colorless oil (503 mg, 68%).

# (C) Analytical Characterization Data of Products



Methyl benzyl-L-prolyl-L-leucinate 5a.

Obtained as a colorless oil by column chromatography (PE/EA = 4/1- 2/1), yield 91%. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.86 (br, 1H), 7.41 – 7.31 (m, 4H), 7.31 – 7.27 (m, 1H), 4.75 – 4.60 (m, 1H), 4.02 (d, *J* = 12.2 Hz, 1H), 3.72 (s, 3H), 3.37 (d, *J* = 12.2 Hz, 1H), 3.25 – 3.15 (m, 1H), 2.99 – 2.91 (m, 1H), 2.38 – 2.18 (m, 2H), 1.83 – 1.53 (m, 6H), 0.99 – 0.93 (m, 6H) ppm. <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 174.45, 173.32, 138.58, 129.03, 128.43, 127.24, 67.35, 59.62, 53.34, 52.18, 50.01, 41.77, 30.71, 25.03, 23.99, 22.89, 21.92 ppm.




# Methyl benzyl-L-prolylglycinate 5b.

Obtained as a colorless oil by column chromatography (PE/EA = 4/1- 2/1), yield 88%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.93 (br, 1H), 7.38 – 7.30 (m, 4H), 7.29 – 7.25 (m, 1H), 4.05 – 3.99 (m, 2H), 3.95 (d, *J* = 13.0 Hz, 1H), 3.75 (s, 3H), 3.49 (d, *J* = 13.0 Hz, 1H), 3.30 – 3.15 (m, 1H), 3.10 – 2.95 (m, 1H), 2.42 – 2.30 (m, 1H), 2.29 – 2.17 (m, 1H), 1.99 – 1.85 (m, 1H), 1.82 – 1.70 (m, 2H) ppm. <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 175.06, 170.31, 138.39, 128.88, 128.41, 127.28, 67.13, 59.73, 53.68, 52.23, 40.71, 30.54, 23.96 ppm.


Methyl benzyl-L-prolyl-L-alaninate 5c.

Obtained as a colorless oil by column chromatography (PE/EA = 4/1- 2/1), yield 91%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.99 (br, 1H), 7.40 – 7.28 (m, 4H), 7.26 – 7.21 (m, 1H), 4.62 – 4.52 (m, 1H), 3.98 (d, J = 12.5 Hz, 1H), 3.72 (s, 3H), 3.36 (d, J = 12.5 Hz, 1H), 3.20 – 3.12 (m, 1H), 2.98 – 2.90 (m, 1H), 2.34 – 2.15 (m, 2H), 1.85 – 1.65 (m, 3H), 1.40 (d, J = 7.2 Hz, 3H) ppm. <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 174.38, 173.32, 138.55, 128.97, 128.37, 127.22, 67.26, 59.70, 53.43, 52.34, 47.39, 30.59, 23.90, 18.63 ppm.




# Methyl benzyl-L-prolyl-L-valinate 5d.

Obtained as a colorless oil by column chromatography (PE/EA = 4/1- 2/1), yield 95%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.06 (d, J = 9.6 Hz, 1H), 7.41 – 7.30 (m, 4H), 7.30 – 7.24 (m, 1H), 4.56 (dd, J = 9.6, 4.8 Hz, 1H), 4.01 (d, J = 12.5 Hz, 1H), 3.71 (s, 3H), 3.38 (d, J = 12.5 Hz, 1H), 3.21 (dd, J = 10.1, 5.0 Hz, 1H), 2.97 (t, J = 7.6 Hz, 1H), 2.37 – 2.17 (m, 3H), 1.92 – 1.83 (m, 1H), 1.75 – 1.65 (m, 1H), 0.99 – 0.88 (m, 6H) ppm. <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 174.68, 172.25, 138.57, 128.95, 128.36, 127.19, 67.35, 59.70, 56.30, 53.39, 51.99, 31.37, 30.92, 24.07, 19.09, 17.64 ppm.




# Methyl benzyl-L-prolyl-L-alloisoleucinate 5e.

Obtained as a colorless oil by column chromatography (PE/EA = 4/1- 2/1), yield 90%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.05 (d, *J* = 9.5 Hz, 1H), 7.42 – 7.29 (m, 4H), 7.28 – 7.23 (m, 1H), 4.60 (dd, *J* = 9.5, 4.8 Hz, 1H), 4.01 (d, *J* = 12.6 Hz, 1H), 3.71 (s, 3H), 3.38 (d, *J* = 12.6 Hz, 1H), 3.20 (dd, *J* = 10.2, 5.0 Hz, 1H), 2.97 (t, *J* = 7.8 Hz, 1H), 2.38 – 2.16 (m, 2H), 2.01 – 1.63 (m, 4H), 1.52 – 1.37 (m, 1H), 1.25 – 1.10 (m, 1H), 0.96 – 0.88 (m, 6H) ppm. <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 174.52, 172.25, 138.59, 128.94, 128.36, 127.18, 67.36, 59.68, 55.75, 53.39, 51.94, 37.95, 30.87, 25.04, 24.06, 15.62, 11.57 ppm.




# Methyl benzyl-L-prolyl-L-serinate 5f.

Obtained as a colorless oil by column chromatography (DCM/MeOH = 40/1- 20/1), yield 81%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.34 (br, 1H), 7.41 – 7.26 (m, 5H), 4.57 (dt, J = 7.7, 4.0 Hz, 1H), 4.06 – 3.87 (m, 3H), 3.78 (s, 3H), 3.47 (d, J = 12.4 Hz, 1H), 3.26 - 3.20 (m, 1H), 3.05 - 2.90 (m, 2H), 2.43 - 2.17 (m, 2H), 1.99 - 1.85 (m, 1H), 1.82 - 1.72 (m, 2H) ppm. <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ 170.56, 129.15, 128.47, 127.50, 67.25, 63.68, 59.52, 54.77, 53.55, 52.67, 30.53, 23.74 ppm.




# Methyl benzyl-L-prolyl-L-phenylalaninate 5g.

Obtained as a colorless oil by column chromatography (PE/EA = 4/1- 2/1), yield 87%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.95 (d, *J* = 8.5 Hz, 1H), 7.28 – 7.21 (m, 6H), 7.19 – 7.09 (m, 4H), 4.95 – 4.87 (m, 1H), 3.92 (d, *J* = 12.6 Hz, 1H), 3.70 (s, 3H), 3.32 (d, *J* = 12.6 Hz, 1H), 3.23 – 3.09 (m, 3H), 2.85 (t, *J* = 8.0 Hz, 1H), 2.29 – 2.09 (m, 2H), 1.78 – 1.64 (m, 2H), 1.62 – 1.50 (m, 1H) ppm. <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 174.10, 171.66, 138.28, 135.76, 129.08, 128.60, 128.27, 128.09, 126.87, 66.89, 59.39, 53.11, 52.01, 51.96, 37.89, 30.31, 23.83 ppm.




#### Methyl benzyl-L-prolyl-L-tryptophanate 5h.

Obtained as a colorless oil by column chromatography (PE/EA = 4/1- 2/1), yield 78%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.94 (br, 1H), 7.84 (s, 1H), 7.56 (d, *J* = 8.1 Hz, 1H), 7.25 – 7.05 (m, 6H), 6.97 – 6.90 (m, 2H), 6.86 (s, 1H), 4.98 – 4.85 (m, 1H), 3.72 (s, 3H), 3.57 (d, *J* = 12.9 Hz, 1H), 3.44 – 3.32 (m, 1H), 3.31 – 3.22 (m, 2H), 3.21 – 3.13 (m, 1H), 2.95 – 2.87 (m, 1H), 2.28 – 2.14 (m, 2H), 1.97 – 1.87 (m, 1H), 1.77 – 1.60 (m, 2H) ppm. <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ 174.56, 172.59, 138.58, 136.08, 128.40, 128.22, 126.97, 122.18, 119.57, 118.63, 111.17, 110.25, 67.33, 59.46, 53.62, 52.36, 52.13, 30.56, 27.56, 24.03 ppm.




(2S)-1-benzyl-2-(((S)-1-methoxy-4-methyl-1-oxopentan-2-yl)carbamoyl)pyrrolidi ne 1-oxide 1a.

Obtained as a white solid by column chromatography (DCM/MeOH = 40/1- 20/1), yield 97%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.96 (br, 1H), 7.48 – 7.39 (m, 5H), 4.82 (d, J = 13.1 Hz, 1H), 4.68 – 4.56 (m, 2H), 3.75 (s, 3H), 3.65 – 3.55 (m, 1H), 3.43 – 3.33 (m, 1H), 3.27 – 3.20 (m, 1H), 2.50 – 2.27 (m, 3H), 1.86 – 1.72 (m, 4H), 0.99 – 0.92 (m, 6H) ppm.




(2S)-1-benzyl-2-((2-methoxy-2-oxoethyl)carbamoyl)pyrrolidine 1-oxide 1b. Obtained as a white solid by column chromatography (DCM/MeOH = 40/1- 20/1), yield 95%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  11.72 (br, 1H), 7.51 – 7.37 (m, 5H), 4.80 (d, J = 13.1 Hz, 1H), 4.62 (d, J = 13.1 Hz, 1H), 4.30 (dd, J = 17.7, 7.2 Hz, 1H), 3.86 (dd, J = 17.7, 4.8 Hz, 1H), 3.80 – 3.66 (m, 4H), 3.45 – 3.27 (m, 2H), 2.49 – 2.30 (m, 3H), 1.92 – 1.80 (m, 1H) ppm. <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  170.11, 168.87, 132.33, 129.88, 129.82, 128.93, 71.58, 70.17, 65.68, 52.24, 40.43, 26.70, 19.80 ppm.




 $(2S) \hbox{-} 1 \hbox{-} benzyl \hbox{-} 2 \hbox{-} (((S) \hbox{-} 1 \hbox{-} methoxy \hbox{-} 1 \hbox{-} oxopropan \hbox{-} 2 \hbox{-} yl) carbamoyl) pyrrolidine$ 

## 1-oxide 1c.

Obtained as a colorless oil by column chromatography (DCM/MeOH = 40/1- 20/1), yield 95%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.70 (br, 1H), 7.49 – 7.39 (m, 5H), 4.85 (d, J = 13.2 Hz, 1H), 4.72 – 4.53 (m, 2H), 3.76 (s, 3H), 3.68 – 3.58 (m, 1H), 3.43 – 3.25 (m, 2H), 2.50 – 2.30 (m, 3H), 1.89 – 1.80 (m, 1H), 1.50 (d, J = 7.4 Hz, 3H) ppm. <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 172.77, 167.63, 131.90, 129.56, 129.31, 128.50, 70.94, 69.55, 64.89, 51.89, 47.06, 26.16, 19.30, 16.83 ppm.




(2S)-1-benzyl-2-(((S)-1-methoxy-3-methyl-1-oxobutan-2-yl)carbamoyl)pyrrolidin e 1-oxide 1d. Obtained as a colorless oil by column chromatography (DCM/MeOH = 40/1- 20/1), yield 98%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 12.02 (br, 1H), 7.50 – 7.36 (m, 5H), δ 4.79 (d, J = 13.1 Hz, 1H), 4.69 (d, J = 13.1 Hz, 1H), 4.48 (dd, J = 7.9, 4.3 Hz, 1H), 3.83 – 3.67 (m, 3H), 3.48 – 3.35 (m, 1H), 3.27 (t, J = 9.2 Hz, 1H), 2.54 – 2.30 (m, 4H), 1.92 – 1.80 (m, 1H), 1.05 – 0.96 (m, 6H) ppm. <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 172.25, 168.66, 132.32, 130.03, 129.71, 128.89, 71.74, 69.85, 65.43, 57.33, 52.08, 30.00, 26.89, 19.80, 19.50, 17.65 ppm.




# (2S)-1-benzyl-2-(((2S,3R)-1-methoxy-3-methyl-1-oxopentan-2-yl)carbamoyl)pyrr olidine 1-oxide 1e.

Obtained as a colorless oil by column chromatography (DCM/MeOH = 40/1- 20/1), yield 95%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  12.01 (br, 1H), 7.48 – 7.43 (m, 2H), 7.42 – 7.37 (m, 3H), 4.80 (d, J = 13.1 Hz, 1H), 4.69 (d, J = 13.1 Hz, 1H), 4.57 – 4.47 (m, 1H), 3.74 (s, 3H), 3.51 – 3.33 (m, 2H), 3.28 (t, J = 9.4 Hz, 1H), 2.53 – 2.29 (m, 3H), 2.14 – 2.03 (m, 1H), 1.92 – 1.79 (m, 1H), 1.53 – 1.41 (m, 1H), 1.38 – 1.26 (m, 1H), 1.23 – 1.15 (m, 2H), 1.01 (d, J = 6.9 Hz, 3H), 0.93 (t, J = 7.3 Hz, 3H) ppm. <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  172.30, 168.55, 132.32, 130.04, 129.71, 128.91, 71.64, 69.85, 65.35, 56.76, 52.06, 36.66, 26.83, 25.05, 19.78, 16.27, 11.76 ppm.




(2S)-1-benzyl-2-(((S)-3-hydroxy-1-methoxy-1-oxopropan-2-yl)carbamoyl)pyrroli dine 1-oxide 1f.

Obtained as a foamy solid by column chromatography (DCM/MeOH = 30/1- 20/1), yield 86%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.23 (d, J = 8.1 Hz, 1H), 7.49 – 7.37 (m, 5H), 4.93 (d, J = 13.2 Hz, 1H), 4.75 – 4.61 (m, 2H), 4.10 (dd, J = 11.5, 4.1 Hz, 1H), 3.92 (dd, J = 11.5, 3.0 Hz, 1H), 3.81 – 3.72 (m, 4H), 3.49 – 3.27 (m, 2H), 2.97 – 2.74 (m, 1H), 2.55 – 2.42 (m, 1H), 2.40 – 2.26 (m, 2H), 1.95 – 1.80 (m, 1H) ppm. <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 170.87, 168.11, 132.42, 129.93, 129.58, 129.02, 71.55, 69.63, 65.13, 61.79, 54.65, 52.54, 26.43, 19.68 ppm.




(2S)-1-benzyl-2-(((S)-1-methoxy-1-oxo-3-phenylpropan-2-yl)carbamoyl)pyrrolidi ne 1-oxide 1g.

Obtained as a faint yellow oil by column chromatography (DCM/MeOH = 50/1- 30/1), yield 92%. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 12.01 (d, J = 7.3 Hz, 1H), 7.41 – 7.36 (m, 5H), 7.33 – 7.26 (m, 2H), 7.26 – 7.19 (m, 3H), 4.85 – 4.79 (m, 1H), δ 4.63 (d, J = 13.1 Hz, 1H), 4.56 (d, J = 13.1 Hz, 1H), 3.74 (s, 3H), 3.63 – 3.54 (m, 1H), 3.37 – 3.17 (m, 3H), 3.13 – 3.05 (m, 1H), 2.35 – 2.25 (m, 1H), 2.24 – 2.14 (m, 2H), 1.88 – 1.69 (m, 1H) ppm. <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 171.98, 168.18, 136.50, 132.27, 130.07, 129.63, 129.28, 128.80, 128.46, 126.87, 71.89, 69.88, 65.45, 53.27, 52.28, 37.55, 26.55, 19.74 ppm.




(2S)-2-(((S)-3-(1H-indol-3-yl)-1-methoxy-1-oxopropan-2-yl)carbamoyl)-1-benzylp yrrolidine 1-oxide 1h.

Obtained as a faint yellow oil by column chromatography (DCM/MeOH = 50/1- 30/1), yield 84%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.15 (d, J = 7.1 Hz, 1H), 9.50 (s, 1H), 7.62 – 7.56 (m, 1H), 7.39 – 7.27 (m, 3H), 7.22 – 7.16 (m, 2H), 7.15 – 7.09 (m, 2H), 7.08 – 6.99 (m, 2H), 4.94 – 4.86 (m, 1H), 4.26 (d, J = 13.1 Hz, 1H), 4.06 (d, J = 13.1 Hz, 1H), 3.71 (s, 3H), 3.69 – 3.63 (m, 1H), 3.35 – 3.24 (m, 4H), 2.48 – 2.35 (m, 1H), 2.34 – 2.20 (m, 2H), 1.85 – 1.73 (m, 1H) ppm. <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 172.07, 167.76, 136.44, 132.10, 129.79, 129.41, 128.79, 127.08, 124.01, 121.81, 119.24, 118.55, 111.38, 109.69, 71.95, 69.93, 66.12, 52.36, 27.36, 26.78, 19.66 ppm.




# (2S)-1-benzyl-2-((2-(((S)-1-methoxy-3-methyl-1-oxobutan-2-yl)amino)-2-oxoethyl )carbamoyl)pyrrolidine 1-oxide 1i.

Obtained as a colorless oil by column chromatography (DCM/MeOH = 40/1- 20/1), yield 81%.<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 11.29 (br, 1H), 7.49 – 7.45 (m, 2H), 7.43 – 7.38 (m, 3H), 6.85 (d, *J* = 8.7 Hz, 1H), 4.69 (d, *J* = 13.0 Hz, 1H), 4.58 (d, *J* = 13.0 Hz, 1H), 4.53 (dd, *J* = 8.8, 5.1 Hz, 1H), 3.94 – 3.91 (m, 2H), 3.90 – 3.85 (m, 1H), 3.70 (s, 3H), 3.46 – 3.36 (m, 2H), 2.47 – 2.35 (m, 3H), 2.19 – 2.12 (m, 1H), 1.94 – 1.87 (m, 1H), 0.93 (d, *J* = 6.9 Hz, 3H), 0.90 (d, *J* = 6.9 Hz, 3H) ppm. <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ 172.37, 169.08, 168.85, 132.37, 129.94, 129.59, 128.86, 72.03, 70.51, 66.33, 57.12, 52.12, 42.80, 31.18, 27.05, 19.87, 18.86, 17.81 ppm.




(2S)-1-benzyl-2-((2-(((2S)-1-methoxy-3-methyl-1-oxopentan-2-yl)amino)-2-oxoeth yl)carbamoyl)pyrrolidine 1-oxide 1j.

Obtained as a colorless oil by column chromatography (DCM/MeOH = 40/1- 20/1), yield 83%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 11.36 (br, 1H), 7.47 – 7.44 (m, 2H), 7.43 – 7.39 (m, 3H), 6.82 (d, *J* = 8.6 Hz, 1H), 4.66 (d, *J* = 13.0 Hz, 1H), 4.59 – 4.56 (m, 1H), 4.55 (d, *J* = 13.0 Hz, 1H), 3.91 (d, *J* = 4.2 Hz, 2H), 3.77 – 3.72 (m, 1H), 3.70 (s, 3H), 3.41 – 3.36 (m, 2H), 2.48 – 2.34 (m, 3H), 1.92 – 1.85 (m, 2H), 1.45 – 1.38 (m, 1H), 1.20 – 1.13 (m, 1H), 0.93 – 0.86 (m, 6H) ppm. <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ 172.35, 169.06, 168.80, 132.36, 129.91, 129.73, 128.86, 72.06, 70.66, 66.41, 56.42, 52.08,




Methyl ((2S,5R)-1-benzyl-5-(1H-indol-3-yl)pyrrolidine-2-carbonyl)-L-leucinate 3a.

Colorless oil, combined yield 70%.  $[\alpha]^{25}{}_{D} = +20.7$  (c = 0.26, CHCl<sub>3</sub>). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  8.36 (br, 1H), 7.94 (d, J = 8.2 Hz, 1H), 7.75 (d, J = 7.9 Hz, 1H), 7.43 (d, J = 8.1 Hz, 1H), 7.35 (d, J = 2.3 Hz, 1H), 7.25 – 7.19 (m, 4H), 7.18 – 7.13 (m, 3H), 4.50 – 4.46 (m, 1H), 4.22 – 4.18 (m, 1H), 3.98 (d, J = 13.5 Hz, 1H), 3.73 (s, 3H), 3.69 (d, J = 13.5 Hz, 1H), 3.52 (dd, J = 10.3, 3.2 Hz, 1H), 2.29 – 2.14 (m, 2H), 2.07 – 1.96 (m, 2H), 1.71 – 1.55 (m, 3H), 0.95 (d, J = 6.3, 6H) ppm. <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  174.92, 173.17, 136.93, 136.26, 130.15, 128.07, 127.16, 126.26, 122.14, 122.08, 119.35, 116.99, 111.50, 64.84, 61.41, 55.97, 52.13, 50.33, 41.78, 32.68, 29.79, 24.96, 22.77, 22.21 ppm. HRMS (ESI) m/z: calculated for C<sub>27</sub>H<sub>34</sub>N<sub>3</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup>: 448.2595, found: 448.2603. The dr was determined by HPLC with an Eclipse XDB-C18 column (5 µm, 4.6 × 150 mm) (H<sub>2</sub>O/MeOH = 30/70,  $\lambda$  = 214 nm, 1.0 mL/min). t<sub>R</sub> (major diastereomer) = 11.145 min, t<sub>R</sub> (minor diastereomer) = 20.616 min, 93:7 dr.



Methyl ((2S,5R)-1-benzyl-5-(6-methyl-1H-indol-3-yl)pyrrolidine-2-carbonyl)-L-le ucinate 3b.


Colorless oil, combined yield 62%.  $[\alpha]^{25}_{D} = + 21.6$  (c = 0.28, CHCl<sub>3</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.24 (br, 1H), 7.93 (d, J = 8.2 Hz, 1H), 7.63 (d, J = 8.1 Hz, 1H), 7.27 – 7.14 (m, 7H), 6.99 (d, J = 8.1 Hz, 1H), 4.53 – 4.45 (m, 1H), 4.20 – 4.13 (m, 1H), 3.98 (d, J = 13.4 Hz, 1H), 3.73 (s, 3H), 3.68 (d, J = 13.4 Hz, 1H), 3.57 – 3.46 (m, 1H), 2.50 (s, 3H), 2.31 – 2.09 (m, 2H), 2.06 – 1.93 (m, 2H), 1.74 – 1.53 (m, 3H), 0.95 (d, J = 5.9 Hz, 6H) ppm. <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  174.87, 173.07, 137.33, 136.14, 131.89, 130.11, 127.97, 127.05, 123.97, 121.43, 121.02, 118.92, 116.66, 111.36, 64.62, 61.30, 55.70, 52.03, 50.22, 41.68, 32.52, 29.69, 24.88, 22.70, 22.10, 21.57 ppm. HRMS (ESI) m/z: calculated for C<sub>28</sub>H<sub>36</sub>N<sub>3</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup>: 462.2757, found: 462.2758. The dr was determined by HPLC with an Eclipse XDB-C18 column (5 µm, 4.6 × 150 mm) (H<sub>2</sub>O/MeOH = 30/70,  $\lambda$  = 214 nm, 1.0 mL/min). t<sub>R</sub> (major diastereomer) = 9.325 min, t<sub>R</sub> (minor diastereomer) = 12.382 min, 94:6 dr.



# Methyl ((2S,5R)-1-benzyl-5-(7-methyl-1H-indol-3-yl)pyrrolidine-2-carbonyl)-L-le ucinate 3c.

Colorless oil, combined yield 68%.  $[\alpha]^{25}_{D} = +24.2$  (c = 0.22, CHCl<sub>3</sub>). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  8.23 (br, 1H), 7.94 (d, J = 8.2 Hz, 1H), 7.60 (d, J = 7.4 Hz, 1H), 7.37


(d, J = 2.3 Hz, 1H), 7.25 – 7.19 (m, 3H), 7.18 – 7.14 (m, 2H), 7.11 – 7.04 (m, 2H), 4.51 – 4.44 (m, 1H), 4.23 – 4.18 (m, 1H), 3.99 (d, J = 13.5 Hz, 1H), 3.74 (s, 3H), 3.69 (d, J = 13.5 Hz, 1H), 3.54 – 3.47 (m, 1H), 2.53 (s, 3H), 2.31 – 2.21 (m, 1H), 2.21 – 2.13 (m, 1H), 2.05 – 1.95 (m, 2H), 1.70 – 1.54 (m, 3H), 0.94 (d, J = 6.3, 6H) ppm. <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  174.91, 173.18, 136.50, 136.29, 130.18, 128.07, 127.16, 125.83, 122.70, 121.75, 120.68, 119.64, 117.61, 117.09, 64.82, 61.46, 55.93, 52.11, 50.36, 41.81, 32.75, 29.83, 24.96, 22.77, 22.23, 16.63 ppm. HRMS (ESI) m/z: calculated for C<sub>28</sub>H<sub>36</sub>N<sub>3</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup>: 462.2751, found: 462.2756. The dr was determined by HPLC with an Eclipse XDB-C18 column (5 µm, 4.6 × 150 mm) (H<sub>2</sub>O/MeOH = 30/70,  $\lambda$  = 214 nm, 1.0 mL/min). t<sub>R</sub> (major diastereomer) = 5.375 min, t<sub>R</sub> (minor diastereomer) = 7.3 min, 93:7 dr.



Methyl ((2S,5R)-1-benzyl-5-(7-ethyl-1H-indol-3-yl)pyrrolidine-2-carbonyl)-L-leu cinate 3d.

Colorless oil, combined yield 71%.  $[\alpha]^{25}{}_{D} = + 18.9$  (c = 0.22, CHCl<sub>3</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.34 (br, 1H), 7.97 (d, J = 8.2 Hz, 1H), 7.64 – 7.57 (m, 1H), 7.36 (d, J = 2.4 Hz, 1H), 7.24 – 7.08 (m, 7H), 4.51 – 4.45 (m, 1H), 4.23 – 4.18 (m, 1H), 3.99 (d, J = 13.4 Hz, 1H), 3.74 (s, 3H), 3.70 (d, J = 13.4 Hz, 1H), 3.54 – 3.49 (m, 1H), 2.91 (q, J = 7.6 Hz, 2H), 2.30 – 2.12 (m, 2H), 2.05 – 1.95 (m, 2H), 1.73 – 1.56 (m, 3H), 1.41 (t, J = 7.6 Hz, 3H), 0.95 (d, J = 6.2 Hz, 6H) ppm. <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  174.97,

173.20, 136.28, 135.79, 130.19, 128.06, 127.15, 126.90, 126.03, 121.71, 120.66, 119.68, 117.47, 117.10, 64.77, 61.46, 55.90, 52.13, 50.35, 41.80, 32.75, 29.83, 24.98, 24.01, 22.79, 22.22, 13.79 ppm. HRMS (ESI) m/z: calculated for  $C_{29}H_{38}N_3O_3^+$  [M + H]<sup>+</sup>: 476.2913, found: 476.2900. The dr was determined by HPLC with an Eclipse XDB-C18 column (5 µm, 4.6 × 150 mm) (H<sub>2</sub>O/MeOH = 30/70,  $\lambda$  = 214 nm, 1.0 mL/min). t<sub>R</sub> (major diastereomer) = 18.281 min, t<sub>R</sub> (minor diastereomer) = 30.035 min, 93:7 dr.




Methyl ((2S,5R)-1-benzyl-5-(6- methoxy-1H-indol-3-yl)pyrrolidine-2-carbonyl)-

## L-leucinate 3e.


Colorless oil, combined yield 59%.  $[\alpha]^{25}_{D} = + 21.8$  (c = 0.14, CHCl<sub>3</sub>). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  8.08 (br, 1H), 7.88 (d, J = 8.2 Hz, 1H), 7.60 (d, J = 8.7 Hz, 1H), 7.25 – 7.19 (m, 4H), 7.17 – 7.12 (m, 2H), 6.92 (d, J = 2.1 Hz, 1H), 6.81 (dd, J = 8.7, 2.1 Hz, 1H), 4.49 – 4.43 (m, 1H), 4.16 – 4.11 (m, 1H), 3.97 (d, J = 13.5 Hz, 1H), 3.87 (s, 3H), 3.73 (s, 3H), 3.68 (d, J = 13.5 Hz, 1H), 3.53 – 3.46 (m, 1H), 2.31 – 2.19 (m, 1H), 2.18 – 2.09 (m, 1H), 2.05 – 1.92 (m, 2H), 1.67 – 1.53 (m, 3H), 0.93 (d, J = 6.3 Hz, 6H) ppm. <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  174.86, 173.18, 156.59, 137.70, 136.35, 130.17, 128.08, 127.16, 120.81, 120.63, 119.98, 117.14, 109.51, 94.86, 64.93, 61.49, 56.04, 55.67, 52.12, 50.35, 41.82, 32.71, 29.80, 24.97, 22.79, 22.23 ppm. HRMS (ESI) m/z: calculated for C<sub>28</sub>H<sub>36</sub>N<sub>3</sub>O<sub>4</sub><sup>+</sup> [M + H]<sup>+</sup>: 478.2700, found: 478.2711. The dr was

determined by HPLC with an Eclipse XDB-C18 column (5  $\mu$ m, 4.6 × 150 mm) (H<sub>2</sub>O/MeOH = 30/70,  $\lambda$  = 214 nm, 1.0 mL/min). t<sub>R</sub> (major diastereomer) = 9.005 min, t<sub>R</sub> (minor diastereomer) = 19.325 min, 93:7 dr.




Methyl ((2S,5R)-1-benzyl-5-(5-methoxy-1H-indol-3-yl)pyrrolidine-2-carbonyl)-Lleucinate 3f.

Colorless oil, combined yield 80%.  $[\alpha]^{25}_{D} = +10.4$  (c = 0.14, CHCl<sub>3</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.22 (br, 1H), 7.90 (d, J = 8.1 Hz, 1H), 7.35 (s, 1H), 7.31 (d, J = 8.8 Hz, 1H), 7.23 – 7.14 (m, 6H), 6.91 (d, J = 8.8 Hz, 1H), 4.48 – 4.43 (m, 1H), 4.18 – 4.15 (m, 1H), 4.00 (d, J = 13.4 Hz, 1H), 3.88 (s, 3H), 3.73 (s, 3H), 3.70 (d, J = 13.4 Hz, 1H), 3.51 – 3.47 (m, 1H), 2.31 – 2.15 (m, 2H), 1.99 – 1.87 (m, 2H), 1.69 – 1.49 (m, 3H), 0.92 – 0.89 (m, 6H) ppm. <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  174.82, 173.27, 153.89, 136.32, 131.96, 130.14, 128.07, 127.17, 126.96, 122.43, 116.90, 112.02, 111.95, 101.57, 65.02, 61.21, 56.22, 55.99, 52.13, 50.29, 41.83, 32.81, 29.77, 24.93, 22.66, 22.26 ppm. HRMS (ESI) m/z: calculated for C<sub>28</sub>H<sub>36</sub>N<sub>3</sub>O<sub>4</sub><sup>+</sup> [M + H]<sup>+</sup>: 478.2706, found: 478.2711. The dr was determined by HPLC with an Eclipse XDB-C18 column (5 µm, 4.6 × 150 mm) (H<sub>2</sub>O/MeOH = 30/70,  $\lambda$  = 214 nm, 1.0 mL/min). t<sub>R</sub> (major diastereomer) = 15.585 min, t<sub>R</sub> (minor diastereomer) = 28.457 min, 93:7 dr.




Methyl ((2S,5R)-1-benzyl-5-(5-bromo-1H-indol-3-yl)pyrrolidine-2-carbonyl)-L-le ucinate 3g.

Colorless oil, combined yield 69%.  $[\alpha]^{25}_{D} = + 36.7$  (c = 0.30, CHCl<sub>3</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.57 (br, 1H), 7.87 (d, J = 8.2 Hz, 1H), 7.83 (s, 1H), 7.34 – 7.27 (m, 3H), 7.24 – 7.18 (m, 3H), 7.17 – 7.12 (m, 2H), 4.53 – 4.44 (m, 1H), 4.15 – 4.08 (m, 1H), 3.95 (d, J = 13.4 Hz, 1H), 3.73 (s, 3H), 3.68 (d, J = 13.4 Hz, 1H), 3.52 – 3.46 (m, 1H), 2.30 – 2.10 (m, 2H), 2.06 – 1.92 (m, 2H), 1.75 – 1.56 (m, 3H), 0.94 (d, J = 5.9 Hz, 6H) ppm. <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  174.74, 173.13, 135.98, 135.55, 130.11, 128.08, 127.96, 127.24, 124.97, 123.38, 121.87, 116.63, 112.95, 112.66, 64.92, 61.13, 56.02, 52.17, 50.43, 41.73, 32.54, 29.64, 25.00, 22.70, 22.28 ppm. HRMS (ESI) m/z: calculated for C<sub>27</sub>H<sub>32</sub>N<sub>3</sub>O<sub>3</sub>BrNa<sup>+</sup> [M + Na]<sup>+</sup>: 548.1525, found: 548.1534. The dr was determined by HPLC with an Eclipse XDB-C18 column (5 µm, 4.6 × 150 mm) (H<sub>2</sub>O/MeOH = 30/70,  $\lambda$  = 214 nm, 1.0 mL/min). t<sub>R</sub> (major diastereomer) = 11.41 min, t<sub>R</sub> (minor diastereomer) = 15.844 min, 96:4 dr.




Methyl ((2S,5R)-1-benzyl-5-(6-fluoro-1H-indol-3-yl)pyrrolidine-2-carbonyl)-L-leucinate 3h. Colorless oil, combined yield 51%.  $[\alpha]_{D}^{25} = +23.9$  (c = 0.14, CHCl<sub>3</sub>). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  8.37 (br, 1H), 7.87 (d, J = 8.1 Hz, 1H), 7.64 (dd, J = 8.7, 5.3 Hz, 1H), 7.30 (d, J = 2.2 Hz, 1H), 7.23 – 7.18 (m, 3H), 7.16 – 7.12 (m, 2H), 7.10 (dd, J = 9.6, 2.2 Hz, 1H), 6.91 (td, J = 9.2, 2.3 Hz, 1H), 4.47 - 4.42 (m, 1H), 4.16 - 4.13 (m, 1H), 3.96 (d, J = 13.4 Hz, 1H), 3.73 (s, 3H), 3.67 (d, J = 13.4 Hz, 1H), 3.50 (dd, J = 10.3, 3.4 Hz, 1H), 2.31 - 2.21 (m, 1H), 2.20 - 2.12 (m, 1H), 2.05 - 1.92 (m, 2H), 1.69 -1.51 (m, 3H), 0.93 (d, J = 6.3, 6H) ppm. <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  174.81, 173.18, δ 159.95 (d, J = 237.9 Hz), 136.85 (d, J = 12.5 Hz), 136.30, 130.09, 128.09, 127.22, 122.81, 122.31, 120.03 (d, J = 10.0 Hz), 117.18, 108.16 (d, J = 24.2 Hz), 97.76 (d, J = 25.9 Hz), 65.12, 61.51, 56.32, 52.16, 50.36, 41.83, 32.72, 29.77, 24.96, 22.74, 22.26 ppm. HRMS (ESI) m/z: calculated for  $C_{27}H_{33}N_3O_3F^+$  [M + H]<sup>+</sup>: 466.2500, found: 466.2506. The dr was determined by HPLC with an Eclipse XDB-C18 column (5  $\mu$ m, 4.6 × 150 mm) (H<sub>2</sub>O/MeOH = 30/70,  $\lambda$  = 214 nm, 1.0 mL/min).  $t_R$  (major diastereomer) = 18.321 min,  $t_R$  (minor diastereomer) = 29.653 min, >93:7 dr.



Methyl ((2S,5R)-1-benzyl-5-(7-fluoro-1H-indol-3-yl)pyrrolidine-2-carbonyl)-L-leucinate 3i.

Colorless oil, combined yield 46%.  $[\alpha]^{25}_{D} = +38.5$  (c = 0.16, CHCl<sub>3</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.54 (br, 1H), 7.89 (d, J = 8.2 Hz, 1H), 7.49 (d, J = 7.9 Hz, 1H), 7.36


(d, J = 2.3 Hz, 1H), 7.25 – 7.11 (m, 5H), 7.06 – 7.01 (m, 1H), 6.98 – 6.91 (m, 1H), 4.49 – 4.43 (m, 1H), 4.21 – 4.14 (m, 1H), 3.96 (d, J = 13.4 Hz, 1H), 3.73 (s, 3H), 3.69 (d, J = 13.4 Hz, 1H), 3.52 (dd, J = 10.2, 3.4 Hz, 1H), 2.32 – 2.12 (m, 2H), 2.05 – 1.92 (m, 2H), 1.71 – 1.53 (m, 3H), 0.97 – 0.90 (m, 6H) ppm. <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  174.76, 173.19,  $\delta$  149.72 (d, J = 244.2 Hz), 136.22, 130.09, 129.94 (d, J = 5.2 Hz), 128.09, 127.22, 125.26 (d, J = 13.4 Hz), 122.76, 119.65 (d, J = 6.1 Hz), 118.06, 115.13, 106.96 (d, J = 16.2 Hz), 65.11, 61.38, 56.26, 52.15, 50.35, 41.81, 32.71, 29.76, 24.96, 22.75, 22.24 ppm. HRMS (ESI) m/z: calculated for C<sub>27</sub>H<sub>33</sub>N<sub>3</sub>O<sub>3</sub>F<sup>+</sup> [M + H]<sup>+</sup>: 466.2506, found: 466.2502. The dr was determined by HPLC with an Eclipse XDB-C18 column (5 µm, 4.6 × 150 mm) (H<sub>2</sub>O/MeOH = 30/70,  $\lambda$  = 214 nm, 1.0 mL/min). t<sub>R</sub> (major diastereomer) = 17.124 min, t<sub>R</sub> (minor diastereomer) = 24.335 min, 90:10 dr.



Methyl ((2S,5R)-1-benzyl-5-(5-(trifluoromethyl)-1H-indol-3-yl)pyrrolidine-2-carbonyl)-L-leucinate 3j.

Colorless oil, combined yield 41%.  $[\alpha]^{25}_{D} = +17.4$  (c = 0.18, CHCl<sub>3</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.69 (br, 1H), 7.98 (s, 1H), 7.85 (d, J = 8.2 Hz, 1H), 7.52 – 7.39 (m, 3H), 7.21 – 7.12 (m, 5H), 4.54 – 4.44 (m, 1H), 4.22 – 4.15 (m, 1H), 3.96 (d, J = 13.4 Hz, 1H), 3.74 – 3.67 (m, 4H), 3.53 – 3.48 (m, 1H), 2.35 – 2.17 (m, 2H), 2.06 – 1.92 (m, 2H), 1.70 – 1.51 (m, 3H), 0.94 – 0.90 (m, 6H) ppm. <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)


δ 174.61, 173.23, 138.20, 135.97, 130.09, 128.08, 127.27, 125.70, 123.60, 121.68, 118.91, 118.19, 116.92, 111.72, 65.21, 61.05, 56.29, 52.17, 50.38, 41.77, 32.92, 29.65, 24.98, 22.61, 22.24 ppm. HRMS (ESI) m/z: calculated for  $C_{28}H_{33}N_3O_3F_3^+$  [M + H]<sup>+</sup>: 516.2474, found: 516.2480. The dr was determined by HPLC with an Eclipse XDB-C18 column (5 μm, 4.6 × 150 mm) (H<sub>2</sub>O/MeOH = 30/70,  $\lambda$  = 214 nm, 1.0 mL/min). t<sub>R</sub> (major diastereomer) = 15.035 min, t<sub>R</sub> (minor diastereomer) = 22.473 min, 90:10 dr.



Methyl ((2S,5R)-1-benzyl-5-(5-cyano-1H-indol-3-yl)pyrrolidine-2-carbonyl)-L-le ucinate 3k.


Colorless oil, combined yield 26%.  $[\alpha]^{25}_{D} = + 41.1$  (c = 0.28, CHCl<sub>3</sub>). <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  8.96 (br, 1H), 8.05 (s, 1H), 7.88 (d, J = 7.9 Hz, 1H), 7.48 – 7.41 (m, 3H), 7.22 – 7.16 (m, 3H), 7.15 – 7.09 (m, 2H), 4.49 – 4.41 (m, 1H), 4.17 (dd, J = 9.7, 6.1 Hz, 1H), 3.93 (d, J = 13.4 Hz, 1H), 3.75 (s, 3H), 3.68 (d, J = 13.4 Hz, 1H), 3.51 (dd, J = 10.3, 4.0 Hz, 1H), 2.34 – 2.24 (m, 1H), 2.23 – 2.16 (m, 1H), 2.08 – 1.92 (m, 2H), 1.74 – 1.66 (m, 1H), 1.62 – 1.54 (m, 2H), 0.96 – 0.90 (m, 6H) ppm. <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>)  $\delta$  174.51, 173.18, 138.57, 136.10, 130.00, 128.12, 127.37, 126.04, 125.08, 124.89, 124.22, 120.58, 118.14, 112.40, 102.60, 65.48, 61.26, 56.72, 52.26, 50.48, 41.86, 32.89, 29.72, 25.02, 22.65, 22.36 ppm. HRMS (ESI) m/z: calculated for C<sub>28</sub>H<sub>33</sub>N<sub>4</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup>: 473.2553, found: 473.2539. The dr was determined by HPLC

with an Eclipse XDB-C18 column (5  $\mu$ m, 4.6 × 150 mm) (H<sub>2</sub>O/MeOH = 30/70,  $\lambda$  = 214 nm, 1.0 mL/min). t<sub>R</sub> (major diastereomer) = 10.07 min, t<sub>R</sub> (minor diastereomer) = 16.621 min, 92:8 dr.




Methyl ((2S,5R)-1-benzyl-5-(5-nitro-1H-indol-3-yl)pyrrolidine-2-carbonyl)-L-leu cinate 31.

Yellow oil, combined yield 20%.  $[\alpha]^{25}{}_{D} = + 27.4$  (c = 0.26, CHCl<sub>3</sub>). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  8.97 (br, 1H), 8.66 (d, J = 1.9 Hz, 1H), 8.14 (dd, J = 9.0, 2.1 Hz, 1H), 7.86 (d, J = 7.7 Hz, 1H), 7.48 (s, 1H), 7.43 (d, J = 9.0 Hz, 1H), 7.20 – 7.16 (m, 3H), 7.15 – 7.11 (m, 2H), 4.54 – 4.46 (m, 1H), 4.23 – 4.16 (m, 1H), 3.94 (d, J = 13.4 Hz, 1H), 3.76 – 3.69 (m, 4H), 3.55 – 3.48 (m, 1H), 2.32 – 2.20 (m, 2H), 2.08 – 1.91 (m, 2H), 1.71 – 1.59 (m, 3H), 0.94 – 0.91 (m, 6H) ppm. <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  174.45, 173.34, 141.47, 139.83, 135.85, 130.04, 128.10, 127.34, 125.63, 125.00, 119.91, 117.86, 116.56, 111.42, 65.38, 61.02, 56.47, 52.22, 50.40, 41.79, 33.10, 29.64, 25.05, 22.67, 22.27 ppm. HRMS (ESI) m/z: calculated for C<sub>27</sub>H<sub>33</sub>N<sub>4</sub>O<sub>5</sub><sup>+</sup> [M + H]<sup>+</sup>: 493.2451, found: 493.2440. The dr was determined by HPLC with an Eclipse XDB-C18 column (5 µm, 4.6 × 150 mm) (H<sub>2</sub>O/MeOH = 30/70,  $\lambda$  = 214 nm, 1.0 mL/min). t<sub>R</sub> (major diastereomer) = 21.023 min, t<sub>R</sub> (minor diastereomer) = 32.702 min, 91:9 dr.




Methyl ((2S,5R)-1-benzyl-5-(1H-indol-3-yl)pyrrolidine-2-carbonyl)glycinate 3n. Colorless oil, combined yield 63%.  $[α]^{25}_{D} = + 34.4$  (c = 0.16, CHCl<sub>3</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.41 (br, 1H), 7.87 – 7.74 (m, 2H), 7.48 – 7.37 (m, 2H), 7.26 – 7.07 (m, 7H), 4.23 – 4.14 (m, 1H), 4.07 – 3.94 (m, 2H), 3.78 (s, 3H), 3.56 – 3.43 (m, 3H), 2.39 – 2.22 (m, 1H), 2.19 – 1.97 (m, 3H) ppm. <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 175.42, 170.29, 137.28, 136.83, 129.86, 128.17, 127.21, 126.38, 122.42, 122.11, 119.50, 119.41, 116.84, 111.44, 65.69, 62.51, 57.21, 52.23, 40.80, 32.69, 29.76 ppm. HRMS (ESI) m/z: calculated for C<sub>23</sub>H<sub>26</sub>N<sub>3</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup>: 392.1974, found: 392.1966. The dr was determined by HPLC with an Eclipse XDB-C18 column (5 μm, 4.6 × 150 mm) (H<sub>2</sub>O/MeOH = 30/70, λ = 214 nm, 1.0 mL/min). t<sub>R</sub> (major diastereomer) = 8.494 min, t<sub>R</sub> (minor diastereomer) = 12.104 min, 95:5 dr.



Methyl ((2S,5R)-1-benzyl-5-(1H-indol-3-yl)pyrrolidine-2-carbonyl)-L-alaninate 30.

Colorless oil, combined yield 62%.  $[\alpha]^{25}{}_{D} = +59.6 \text{ (c} = 0.064, \text{CHCl}_3\text{)}$ . <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.39 (br, 1H), 8.04 (d, J = 6.2 Hz, 1H), 7.77 (d, J = 7.9 Hz, 1H), 7.46 -7.37 (m, 2H), 7.25 -7.13 (m, 7H), 4.32 -4.24 (m, 1H), 4.23 -4.16 (m, 1H), 4.00 (d,

J = 13.2 Hz, 1H), 3.75 (s, 3H), 3.60 (d, J = 13.2 Hz, 1H), 3.52 – 3.44 (m, 1H), 2.35 – 2.22 (m, 1H), 2.20 – 2.13 (m, 1H), 2.08 – 1.96 (m, 2H), 1.38 (d, J = 7.1 Hz, 3H) ppm. <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  175.02, 173.24, 136.90, 136.76, 130.08, 128.04, 127.16, 126.32, 122.13, 119.37, 117.01, 111.46, 65.35, 62.00, 56.70, 52.30, 47.71, 32.75, 29.75, 18.58 ppm. HRMS (ESI) m/z: calculated for C<sub>24</sub>H<sub>27</sub>N<sub>3</sub>O<sub>3</sub>Na<sup>+</sup> [M + Na]<sup>+</sup>: 428.1950, found: 428.1916. The dr was determined by HPLC with an Eclipse XDB-C18 column (5 µm, 4.6 × 150 mm) (H<sub>2</sub>O/MeOH = 30/70,  $\lambda$  = 214 nm, 1.0 mL/min). t<sub>R</sub> (major diastereomer) = 8.535 min, t<sub>R</sub> (minor diastereomer) = 15.712 min, >94:6 dr.




Methyl ((2S,5R)-1-benzyl-5-(1H-indol-3-yl)pyrrolidine-2-carbonyl)-L-valinate

**3p.** 


Colorless oil, combined yield 58%.  $[\alpha]^{25}{}_{D} = +55.8$  (c = 0.1, CHCl<sub>3</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.33 (br, 1H), 8.11 (d, J = 8.5 Hz, 1H), 7.75 (d, J = 7.9 Hz, 1H), 7.47 – 7.38 (m, 2H), 7.26 – 7.12 (m, 7H), 4.44 – 4.37 (m, 1H), 4.27 – 4.20 (m, 1H), 3.99 (d, J = 13.3 Hz, 1H), 3.75 (s, 3H), 3.70 (d, J = 13.3 Hz, 1H), 3.56 – 3.48 (m, 1H), 2.33 – 2.12 (m, 3H), 2.05 – 1.89 (m, 2H), 0.94 – 0.88 (m, 6H) ppm. <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  175.14, 172.14, 136.85, 136.35, 130.14, 128.05, 127.17, 126.41, 122.17, 121.62, 119.38, 119.30, 117.28, 111.42, 65.10, 61.53, 56.50, 56.32, 51.96, 33.15, 31.64, 30.11, 18.80, 17.81 ppm. HRMS (ESI) m/z: calculated for C<sub>26</sub>H<sub>31</sub>N<sub>3</sub>O<sub>3</sub>Na<sup>+</sup> [M

+ Na]<sup>+</sup>: 456.2263, found: 456.2258. The dr was determined by HPLC with an Eclipse XDB-C18 column (5  $\mu$ m, 4.6  $\times$  150 mm) (H<sub>2</sub>O/MeOH = 30/70,  $\lambda$  = 214 nm, 1.0 mL/min). t<sub>R</sub> (major diastereomer) = 13.557 min, t<sub>R</sub> (minor diastereomer) = 27.517 min, >94:6 dr.




Methyl ((2S,5R)-1-benzyl-5-(1H-indol-3-yl)pyrrolidine-2-carbonyl)-L-alloisoleucinate 3q.

Colorless oil, combined yield 61%.  $[\alpha]^{25}_{D} = + 34.2$  (c = 0.22, CHCl<sub>3</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.31 (br, 1H), 8.10 (d, J = 8.7 Hz, 1H), 7.75 (d, J = 7.9 Hz, 1H), 7.49 – 7.36 (m, 2H), 7.25 – 7.12 (m, 7H), 4.47 – 4.40 (m, 1H), 4.26 – 4.18 (m, 1H), 3.99 (d, J = 13.2 Hz, 1H), 3.75 (s, 3H), 3.69 (d, J = 13.2 Hz, 1H), 3.55 – 3.48 (m, 1H), 2.33 – 2.17 (m, 2H), 2.04 – 1.85 (m, 3H), 1.51 – 1.38 (m, 1H), 1.22 – 1.08 (m, 1H), 0.95 – 0.85 (m, 6H) ppm. <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  174.95, 172.10, 136.88, 136.36, 130.16, 128.05, 127.18, 126.41, 122.18, 121.72, 119.38, 119.35, 117.27, 111.44, 65.10, 61.54, 56.30, 55.91, 51.91, 38.23, 33.09, 30.04, 25.29, 15.31, 11.72 ppm. HRMS (ESI) m/z: calculated for C<sub>27</sub>H<sub>34</sub>N<sub>3</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup>: 448.2600, found: 448.2604. The dr was determined by HPLC with an Eclipse XDB-C18 column (5 µm, 4.6 × 150 mm) (H<sub>2</sub>O/MeOH = 30/70,  $\lambda$  = 214 nm, 1.0 mL/min). t<sub>R</sub> (major diastereomer) = 5.54 min, t<sub>R</sub> (minor diastereomer) = 8.745 min, 95:5 dr.




Methyl ((2S,5R)-1-benzyl-5-(1H-indol-3-yl)pyrrolidine-2-carbonyl)-L-serinate 3r. Colorless oil, combined yield 55%.  $[α]^{25}_{D} = + 34.5$  (c = 0.34, CHCl<sub>3</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.46 (br, 1H), 8.32 (d, J = 5.7 Hz, 1H), 7.75 (d, J = 7.9 Hz, 1H), 7.44 – 7.38 (m, 2H), 7.26 – 7.11 (m, 7H), 4.25 – 4.19 (m, 1H), 4.18 – 4.12 (m, 1H), 4.02 (d, J = 13.0 Hz, 1H), 3.86 – 3.82 (m, 2H), 3.77 (s, 3H), 3.55 (d, J = 13.0 Hz, 1H), 3.53 – 3.46 (m, 1H), 2.37 – 2.23 (m, 1H), 2.23 – 2.13 (m, 1H), 2.08 – 1.91 (m, 3H) ppm. <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 176.62, 170.46, 137.09, 136.74, 129.99, 128.11, 127.27, 126.45, 122.12, 119.43, 119.20, 116.97, 111.43, 65.66, 63.95, 62.32, 57.31, 55.26, 52.66, 32.99, 29.91 ppm. HRMS (ESI) m/z: calculated for C<sub>24</sub>H<sub>28</sub>N<sub>3</sub>O<sub>4</sub><sup>+</sup> [M + H]<sup>+</sup>: 422.2080, found: 422.2089. The dr was determined by HPLC with an Eclipse XDB-C18 column (5 μm, 4.6 × 150 mm) (H<sub>2</sub>O/MeOH = 30/70, λ = 214 nm, 1.0 mL/min). t<sub>R</sub> (major diastereomer) = 7.119 min, t<sub>R</sub> (minor diastereomer) = 9.719 min, 96:4 dr.



Methyl ((2S,5R)-1-benzyl-5-(1H-indol-3-yl)pyrrolidine-2-carbonyl)-L-phenylalaninate 3s.

Colorless oil, combined yield 76%.  $[\alpha]_{D}^{25} = +31.3$  (c = 0.24, CHCl<sub>3</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.19 (br, 1H), 7.95 (d, J = 6.9 Hz, 1H), 7.50 (d, J = 7.8 Hz, 1H), 7.39


(d, J = 8.3 Hz, 1H), 7.25 – 7.18 (m, 4H), 7.17 – 7.12 (m, 3H), 7.11 – 7.03 (m, 5H), 7.02 (t, J = 7.4 Hz, 1H), 4.67 – 4.57 (m, 1H), 4.18 – 4.08 (m, 1H), 3.89 (d, J = 13.1 Hz, 1H), 3.73 (s, 3H), 3.55 (d, J = 13.1 Hz, 1H), 3.51 - 3.42 (m, 1H), 3.26 - 3.17 (m, 1H), 3.13 – 3.04 (m, 1H), 2.33 – 2.19 (m, 1H), 2.17 – 2.05 (m, 1H), 2.00 – 1.81 (m, 2H) ppm. <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  174.78, 171.59, 136.71, 136.51, 135.98, 130.11, 129.31, 128.38, 127.94, 127.11, 126.97, 126.30, 122.14, 122.01, 119.41, 119.34, 116.84, 111.26, 65.15, 61.73, 56.51, 52.73, 52.13, 37.88, 32.80, 29.74 ppm. HRMS (ESI) m/z: calculated for C<sub>30</sub>H<sub>32</sub>N<sub>3</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup>: 482.2444, found: 482.2453. The dr was determined by HPLC with an Eclipse XDB-C18 column (5 µm, 4.6 × 150 mm) (H<sub>2</sub>O/MeOH = 30/70,  $\lambda$  = 214 nm, 1.0 mL/min). t<sub>R</sub> (major diastereomer) = 15.998 min, t<sub>R</sub> (minor diastereomer) = 35.412 min, >96:4 dr.



Methyl ((2S,5R)-1-benzyl-5-(1H-indol-3-yl)pyrrolidine-2-carbonyl)-L-tryptophanate 3t.

Dark red oil, combined yield 59%.  $[\alpha]^{25}{}_{D} = -7.1$  (c = 0.22, CHCl<sub>3</sub>). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  8.33 (br, 1H), 8.23 (s, 1H), 8.05 (d, J = 8.0 Hz, 1H), 7.67 (d, J = 7.9 Hz, 1H), 7.57 (d, J = 7.9 Hz, 1H), 7.42 - 7.33 (m, 2H), 7.24 - 7.18 (m, 2H), 7.16 - 7.05 (m, 5H), 6.99 - 6.93 (m, 2H), 6.89 - 6.82 (m, 2H), 4.80 - 4.73 (m, 1H), 4.19 - 4.11 (m, 1H), 3.73 - 3.67 (m, 2H), 3.63 (s, 3H), 3.59 - 3.53 (m, 1H), 3.50 (d, J = 13.5 Hz, 1H),  $\delta$  3.18 (dd, J = 14.9, 5.8 Hz, 1H), 3.09 (dd, J = 14.9, 6.3 Hz, 1H), 2.22 - 2.04


(m, 3H), 1.95 - 1.85 (m, 1H) ppm. <sup>13</sup>C NMR (125MHz, CDCl<sub>3</sub>)  $\delta$  175.27, 172.76, 136.74, 136.56, 136.19, 136.09, 129.83, 128.23, 127.57, 127.24, 126.58, 122.77, 122.20, 122.09, 121.94, 119.64, 119.34, 119.13, 118.80, 117.01, 111.31, 111.19, 110.06, 65.11, 61.31, 56.32, 52.23, 32.91, 29.99, 27.48 ppm. HRMS (ESI) m/z: calculated for C<sub>32</sub>H<sub>32</sub>N<sub>4</sub>O<sub>3</sub>Na<sup>+</sup> [M + Na]<sup>+</sup>: 543.2372, found: 543.2361. The dr was determined by HPLC with an Eclipse XDB-C18 column (5 µm, 4.6 × 150 mm) (H<sub>2</sub>O/MeOH = 30/70,  $\lambda$  = 214 nm, 1.0 mL/min). t<sub>R</sub> (major diastereomer) = 13.21 min, t<sub>R</sub> (minor diastereomer) = 21.701 min, >97:3 dr.



Methyl ((2S,5R)-1-benzyl-5-(1H-indol-3-yl)pyrrolidine-2-carbonyl)glycyl-L-valin ate 3u.

Colorless oil, combined yield 47%.  $[\alpha]^{25}{}_{D} = +22.2$  (c = 0.24, CHCl<sub>3</sub>). <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  8.45 (br, 1H), 7.85 – 7.78 (m, 1H), 7.72 (d, J = 7.9 Hz, 1H), 7.45 – 7.42 (m, 2H), 7.34 – 7.30 (m, 1H), 7.23 – 7.16 (m, 4H), 7.13 – 7.07 (m, 2H), 6.80 (d, J = 8.5 Hz, 1H), 4.51 (dd, J = 8.7, 5.0 Hz, 1H), 4.22 – 4.15 (m, 1H), 4.00 (d, J = 12.1 Hz, 1H), 3.86 (dd, J = 16.4, 6.1 Hz, 1H), 3.69 (s, 3H), 3.52 – 3.45 (m, 2H), 3.34 (dd, J = 16.4, 4.7 Hz, 1H), 2.37 – 2.28 (m, 1H), 2.20 – 2.13 (m, 2H), 2.06 – 1.98 (m, 2H), 0.95 (d, J = 6.9 Hz, 3H), 0.91 (d, J = 6.9 Hz, 3H) ppm. <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>)  $\delta$  176.24, 172.07, 169.05, 137.44, 136.74, 129.73, 128.31, 127.31, 126.48, 122.38,

122.13, 119.57, 119.09, 116.73, 111.47, 65.89, 62.56, 57.52, 57.18, 52.12, 43.00, 32.78, 31.02, 29.86, 18.92, 17.69 ppm. HRMS (ESI) m/z: calculated for  $C_{28}H_{35}N_4O_4^+$  $[M + H]^+$ : 491.2658, found: 491.2644. The dr was determined by HPLC with an Eclipse XDB-C18 column (5 µm, 4.6 × 150 mm) (H<sub>2</sub>O/MeOH = 30/70,  $\lambda$  = 214 nm, 1.0 mL/min). t<sub>R</sub> (major diastereomer) = 11.094 min, t<sub>R</sub> (minor diastereomer) = 17.325 min, 95:5 dr.



Methyl ((2S,5R)-1-benzyl-5-(1H-indol-3-yl)pyrrolidine-2-carbonyl)glycyl-L-alloisleucinate 3v.

Colorless oil, combined yield 42%.  $[\alpha]^{25}_{D} = + 31.5$  (c = 0.24, CHCl<sub>3</sub>). <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  8.43 (br, 1H), 7.83 – 7.77 (m, 1H), 7.72 (d, J = 7.9 Hz, 1H), 7.44 – 7.41 (m, 2H), 7.34 – 7.31 (m, 1H), 7.23 – 7.15 (m, 4H), 7.12 – 7.07 (m, 2H), 6.80 (d, J = 8.5 Hz, 1H), 4.56 (dd, J = 8.6, 4.9 Hz, 1H), 4.21 – 4.17 (m, 1H), 4.00 (d, J = 12.9 Hz, 1H), 3.85 (dd, J = 16.4, 6.2 Hz, 1H), 3.69 (s, 3H), 3.52 – 3.45 (m, 2H), 3.33 (dd, J = 16.4, 5.0 Hz, 1H), 2.38 – 2.26 (m, 1H), 2.21 – 2.12 (m, 1H), 2.08 – 1.98 (m, 2H), 1.91 – 1.88 (m, 1H), 1.45 – 1.37 (m, 1H), 1.21 – 1.14 (m, 1H), 0.94 – 0.88 (m, 6H) ppm. <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>)  $\delta$  176.23, 172.05, 168.94, 137.43, 136.75, 129.73, 128.30, 127.31, 126.47, 122.38, 122.14, 119.58, 119.11, 116.73, 111.46, 65.88, 62.55, 57.51, 56.51, 52.07, 43.02, 37.66, 32.76, 29.86, 25.04, 15.46, 15.43, 11.56, 11.54 ppm.

HRMS (ESI) m/z: calculated for  $C_{29}H_{37}N_4O_4^+$  [M + H]<sup>+</sup>: 505.2815, found: 505.2829. The dr was determined by HPLC with an Eclipse XDB-C18 column (5 µm, 4.6 × 150 mm) (H<sub>2</sub>O/MeOH = 30/70,  $\lambda$  = 214 nm, 1.0 mL/min). t<sub>R</sub> (major diastereomer) = 16.001 min, t<sub>R</sub> (minor diastereomer) = 28.538 min, 95:5 dr.

# (D) The Absolute Configuration of 3d.

X-ray Single Crystal Stucture Analysis of **3d**:

X-ray crystallographic data of **3d** were solutions at T = 130 K. C<sub>29</sub>H<sub>37</sub>N<sub>3</sub>O<sub>3</sub>, triclinic. Space group P1, a = 13.8032(6) Å, b = 14.0849(6) Å, c = 14.8146(6) Å,  $\alpha = 89.715(3)^{\circ}$ ,  $\beta = 77.329(3)^{\circ}$ ,  $\gamma = 77.339(3)^{\circ}$ , V = 2738.9(2) Å<sup>3</sup>, Z = 4.




Figure S1: The crystal structure of 3d by X-ray analysis.


These data can be obtained free of charge from the Cambridge Crystallographic Data

Centre via www.ccdc.cam.ac.uk/data\_request/cif, the CCDC number is 1023777.

# (E) HPLC spectra for dr determination.


## 3a/4a

The dr was determined by HPLC with an Eclipse XDB-C18 column (5  $\mu$ m, 4.6 × 150 mm) (H<sub>2</sub>O/MeOH = 30/70,  $\lambda$  = 214 nm, 1.0 mL/min). t<sub>R</sub> (major diastereomer) = 11.145 min, t<sub>R</sub> (minor diastereomer) = 20.616 min, 93:7 dr.




# 3b/4b

The dr was determined by HPLC with an Eclipse XDB-C18 column (5  $\mu$ m, 4.6 × 150 mm) (H<sub>2</sub>O/MeOH = 30/70,  $\lambda$  = 214 nm, 1.0 mL/min). t<sub>R</sub> (major diastereomer) = 9.325 min, t<sub>R</sub> (minor diastereomer) = 12.382 min, 94:6 dr.




3c/4c

The dr was determined by HPLC with an Eclipse XDB-C18 column (5  $\mu$ m, 4.6 × 150 mm) (H<sub>2</sub>O/MeOH = 30/70,  $\lambda$  = 214 nm, 1.0 mL/min). t<sub>R</sub> (major diastereomer) = 5.375 min, t<sub>R</sub> (minor diastereomer) = 7.3 min, 93:7 dr.




### 3d/4d

The dr was determined by HPLC with an Eclipse XDB-C18 column (5  $\mu$ m, 4.6 × 150 mm) (H<sub>2</sub>O/MeOH = 30/70,  $\lambda$  = 214 nm, 1.0 mL/min). t<sub>R</sub> (major diastereomer) = 18.281 min, t<sub>R</sub> (minor diastereomer) = 30.035 min, 93:7 dr.




3e/4e

The dr was determined by HPLC with an Eclipse XDB-C18 column (5  $\mu$ m, 4.6 × 150 mm) (H<sub>2</sub>O/MeOH = 30/70,  $\lambda$  = 214 nm, 1.0 mL/min). t<sub>R</sub> (major diastereomer) = 9.005 min, t<sub>R</sub> (minor diastereomer) = 19.325 min, 93:7 dr.







The dr was determined by HPLC with an Eclipse XDB-C18 column (5  $\mu$ m, 4.6 × 150 mm) (H<sub>2</sub>O/MeOH = 30/70,  $\lambda$  = 214 nm, 1.0 mL/min). t<sub>R</sub> (major diastereomer) = 15.585 min, t<sub>R</sub> (minor diastereomer) = 28.457 min, 93:7 dr.



### 3g/4g


The dr was determined by HPLC with an Eclipse XDB-C18 column (5  $\mu$ m, 4.6 × 150 mm) (H<sub>2</sub>O/MeOH = 30/70,  $\lambda$  = 214 nm, 1.0 mL/min). t<sub>R</sub> (major diastereomer) = 11.41






#### 3h/4h

The dr was determined by HPLC with an Eclipse XDB-C18 column (5  $\mu$ m, 4.6 × 150 mm) (H<sub>2</sub>O/MeOH = 30/70,  $\lambda$  = 214 nm, 1.0 mL/min). t<sub>R</sub> (major diastereomer) = 18.321 min, t<sub>R</sub> (minor diastereomer) = 29.653 min, >93:7 dr.




The dr was determined by HPLC with an Eclipse XDB-C18 column (5  $\mu$ m, 4.6 × 150 mm) (H<sub>2</sub>O/MeOH = 30/70,  $\lambda$  = 214 nm, 1.0 mL/min). t<sub>R</sub> (major diastereomer) = 17.124 min, t<sub>R</sub> (minor diastereomer) = 24.335 min, 90:10 dr.




### 3j/4j

The dr was determined by HPLC with an Eclipse XDB-C18 column (5  $\mu$ m, 4.6 × 150 mm) (H<sub>2</sub>O/MeOH = 30/70,  $\lambda$  = 214 nm, 1.0 mL/min). t<sub>R</sub> (major diastereomer) = 15.035 min, t<sub>R</sub> (minor diastereomer) = 22.473 min, 90:10 dr.




### 3k/4k

The dr was determined by HPLC with an Eclipse XDB-C18 column (5  $\mu$ m, 4.6 × 150 mm) (H<sub>2</sub>O/MeOH = 30/70,  $\lambda$  = 214 nm, 1.0 mL/min). t<sub>R</sub> (major diastereomer) = 10.07 min, t<sub>R</sub> (minor diastereomer) = 16.621 min, 92:8 dr.






The dr was determined by HPLC with an Eclipse XDB-C18 column (5  $\mu$ m, 4.6 × 150 mm) (H<sub>2</sub>O/MeOH = 30/70,  $\lambda$  = 214 nm, 1.0 mL/min). t<sub>R</sub> (major diastereomer) = 21.023 min, t<sub>R</sub> (minor diastereomer) = 32.702 min, 91:9 dr.




### 3n/4n

The dr was determined by HPLC with an Eclipse XDB-C18 column (5  $\mu$ m, 4.6 × 150 mm) (H<sub>2</sub>O/MeOH = 30/70,  $\lambda$  = 214 nm, 1.0 mL/min). t<sub>R</sub> (major diastereomer) = 8.494 min, t<sub>R</sub> (minor diastereomer) = 12.104 min, 95:5 dr.






The dr was determined by HPLC with an Eclipse XDB-C18 column (5  $\mu$ m, 4.6 × 150 mm) (H<sub>2</sub>O/MeOH = 30/70,  $\lambda$  = 214 nm, 1.0 mL/min). t<sub>R</sub> (major diastereomer) = 8.535 min, t<sub>R</sub> (minor diastereomer) = 15.712 min, >94:6 dr.




# 3p/4p

The dr was determined by HPLC with an Eclipse XDB-C18 column (5  $\mu$ m, 4.6 × 150 mm) (H<sub>2</sub>O/MeOH = 30/70,  $\lambda$  = 214 nm, 1.0 mL/min). t<sub>R</sub> (major diastereomer) = 13.557 min, t<sub>R</sub> (minor diastereomer) = 27.517 min, >94:6 dr.




# 3q/4q

The dr was determined by HPLC with an Eclipse XDB-C18 column (5  $\mu$ m, 4.6 × 150 mm) (H<sub>2</sub>O/MeOH = 30/70,  $\lambda$  = 214 nm, 1.0 mL/min). t<sub>R</sub> (major diastereomer) = 5.54 min, t<sub>R</sub> (minor diastereomer) = 8.745 min, 95:5 dr.




3r/4r

The dr was determined by HPLC with an Eclipse XDB-C18 column (5  $\mu$ m, 4.6 × 150 mm) (H<sub>2</sub>O/MeOH = 30/70,  $\lambda$  = 214 nm, 1.0 mL/min). t<sub>R</sub> (major diastereomer) = 7.119 min, t<sub>R</sub> (minor diastereomer) = 9.719 min, 96:4 dr.




#### 3s/4s

The dr was determined by HPLC with an Eclipse XDB-C18 column (5  $\mu$ m, 4.6 × 150 mm) (H<sub>2</sub>O/MeOH = 30/70,  $\lambda$  = 214 nm, 1.0 mL/min). t<sub>R</sub> (major diastereomer) = 15.998 min, t<sub>R</sub> (minor diastereomer) = 35.412 min, >96:4 dr.




The dr was determined by HPLC with an Eclipse XDB-C18 column (5  $\mu$ m, 4.6 × 150 mm) (H<sub>2</sub>O/MeOH = 30/70,  $\lambda$  = 214 nm, 1.0 mL/min). t<sub>R</sub> (major diastereomer) = 13.21







The dr was determined by HPLC with an Eclipse XDB-C18 column (5  $\mu$ m, 4.6 × 150 mm) (H<sub>2</sub>O/MeOH = 30/70,  $\lambda$  = 214 nm, 1.0 mL/min). t<sub>R</sub> (major diastereomer) = 11.094 min, t<sub>R</sub> (minor diastereomer) = 17.325 min, 95:5 dr.




3v/4v


The dr was determined by HPLC with an Eclipse XDB-C18 column (5  $\mu$ m, 4.6 × 150 mm) (H<sub>2</sub>O/MeOH = 30/70,  $\lambda$  = 214 nm, 1.0 mL/min). t<sub>R</sub> (major diastereomer) = 16.001 min, t<sub>R</sub> (minor diastereomer) = 28.538 min, 95:5 dr.








(F) Copies of <sup>1</sup>H NMR and <sup>13</sup>C NMR Spectra for the Products.
















































































## 





Methyl ((2S,5R)-1-benzyl-5-(5-cyano-1H-indol-3-yl)pyrrolidine-2-carbonyl)-L





## 



















## 





## (G) Reference

1 J. S. Chen, R. Properzi, D. P. Uccello, J. A. Young, R. G. Dushin, J. T. Starr, Org. Lett., 2014, 16, 4146–4149.